Interleukin-29 modulates proinflammatory cytokine production in synovial inflammation of rheumatoid arthritis

Arthritis Research and Therapy

Volumn 14, Issue 5, 2012, Pages

  Wang, Fang ^a   Xu, Lingxiao ^a   Feng, Xiaoke ^a   Guo, Dunming ^a   Tan, Wenfeng ^a   Zhang, Miaojia ^a  

^a THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 10; INTERLEUKIN 29; INTERLEUKIN 6; INTERLEUKIN 8; MESSENGER RNA; STROMELYSIN; CYTOKINE; CYTOKINE RECEPTOR; IL29 PROTEIN, HUMAN; INTERLEUKIN 28ALPHA RECEPTOR; INTERLEUKIN DERIVATIVE;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROBLAST; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; MACROPHAGE; MAJOR CLINICAL STUDY; MALE; OSTEOARTHRITIS; PERIPHERAL BLOOD MONONUCLEAR CELL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RHEUMATOID ARTHRITIS; SYNOVITIS; ADOLESCENT; CASE CONTROL STUDY; CELL CULTURE; DRUG EFFECTS; METABOLISM; MIDDLE AGED; PATHOLOGY; SEVERITY OF ILLNESS INDEX; SYNOVIAL FLUID; SYNOVIUM; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ARTHRITIS, RHEUMATOID; CASE-CONTROL STUDIES; CELLS, CULTURED; CYTOKINES; FEMALE; FIBROBLASTS; HUMANS; INTERLEUKINS; MALE; MATRIX METALLOPROTEINASE 3; MIDDLE AGED; OSTEOARTHRITIS; RECEPTORS, CYTOKINE; SEVERITY OF ILLNESS INDEX; SYNOVIAL FLUID; SYNOVIAL MEMBRANE; SYNOVITIS; YOUNG ADULT;

EID: 84867607105     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar4067     Document Type: Article

References (31)

1. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med 2011, 365:2205-2219. 10.1056/NEJMra1004965, 22150039.
2. Yoshida S, Arakawa F, Higuchi F, Ishibashi Y, Goto M, Sugita Y, Nomura Y, Niino D, Shimizu K, Aoki R, Hashikawa K, Kimura Y, Yasuda K, Tashiro K, Kuhara S, Nagata K, Ohshima K. Gene expression analysis of rheumatoid arthritis synovial lining regions by cDNA microarray combined with laser microdissection: up-regulation of inflammation-associated STAT1, IRF1, CXCL9, CXCL10, and CCL5. Scand J Rheumatol 2012, 41:170-179. 10.3109/03009742.2011.623137, 3400100, 22401175.
3. Higgs BW, Zhu W, Richman L, Fiorentino DF, Greenberg SA, Jallal B, Yao Y. Identification of activated cytokine pathways in the blood of systemic lupus erythematosus, myositis, rheumatoid arthritis, and scleroderma patients. Int J Rheum Dis 2012, 15:25-35.
4. Uze G, Monneron D. IL-28 and IL-29: newcomers to the interferon family. Biochimie 2007, 89:729-734. 10.1016/j.biochi.2007.01.008, 17367910.
5. Sheppard P, Kindsvogel W, Xu W, Henderson K, Schlutsmeyer S, Whitmore TE, Kuestner R, Garrigues U, Birks C, Roraback J, Ostrander C, Dong D, Shin J, Presnell S, Fox B, Haldeman B, Cooper E, Taft D, Gilbert T, Grant FJ, Tackett M, Krivan W, McKnight G, Clegg C, Foster D, Klucher KM. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol 2003, 4:63-68. 10.1038/ni873, 12469119.
6. Mordstein M, Michiels T, Staeheli P. What have we learned from the IL28 receptor knockout mouse?. J Interferon Cytokine Res 2010, 30:579-584. 10.1089/jir.2010.0061, 20649452.
7. Steen HC, Gamero AM. Interferon-lambda as a potential therapeutic agent in cancer treatment. J Interferon Cytokine Res 2010, 30:597-602. 10.1089/jir.2010.0058, 20645876.
8. Huang J, Smirnov SV, Lewis-Antes A, Balan M, Li W, Tang S, Silke GV, Putz MM, Smith GL, Kotenko SV. Inhibition of type I and type III interferons by a secreted glycoprotein from Yaba-like disease virus. Proc Natl Acad Sci USA 2007, 104:9822-9827. 10.1073/pnas.0610352104, 1887573, 17517620.
9. Commins S, Steinke JW, Borish L. The extended IL-10 superfamily: IL-10, IL-19, IL-20, IL-22, IL-24, IL-26, IL-28, and IL-29. J Allergy Clin Immunol 2008, 121:1108-1111. 10.1016/j.jaci.2008.02.026, 18405958.
10. Witte K, Gruetz G, Volk HD, Looman AC, Asadullah K, Sterry W, Sabat R, Wolk K. Despite IFN-lambda receptor expression, blood immune cells, but not keratinocytes or melanocytes, have an impaired response to type III interferons: implications for therapeutic applications of these cytokines. Genes Immun 2009, 10:702-714. 10.1038/gene.2009.72, 19798076.
11. Iversen MB, Paludan SR. Mechanisms of type III interferon expression. J Interferon Cytokine Res 2010, 30:573-578. 10.1089/jir.2010.0063, 20645874.
12. Kotenko SV. IFN-lambdas. Curr Opin Immunol 2011, 23:583-590. 10.1016/j.coi.2011.07.007, 3196341, 21840693.
13. Liu BS, Janssen HL, Boonstra A. IL-29 and IFNalpha differ in their ability to modulate IL-12 production by TLR-activated human macrophages and exhibit differential regulation of the IFNgamma receptor expression. Blood 2011, 117:2385-2395. 10.1182/blood-2010-07-298976, 21190998.
14. Srinivas S, Dai J, Eskdale J, Gallagher GE, Megjugorac NJ, Gallagher G. Interferon-lambda1 (interleukin-29) preferentially down-regulates interleukin-13 over other T helper type 2 cytokine responses in vitro. Immunology 2008, 125:492-502. 10.1111/j.1365-2567.2008.02862.x, 2612545, 18547367.
15. Jordan WJ, Eskdale J, Srinivas S, Pekarek V, Kelner D, Rodia M, Gallagher G. Human interferon lambda-1 (IFN-lambda1/IL-29) modulates the Th1/Th2 response. Genes Immun 2007, 8:254-261. 10.1038/sj.gene.6364382, 17361203.
16. Jordan WJ, Eskdale J, Boniotto M, Rodia M, Kellner D, Gallagher G. Modulation of the human cytokine response by interferon lambda-1 (IFN-lambda1/IL-29). Genes Immun 2007, 8:13-20. 10.1038/sj.gene.6364348, 17082759.
17. Mennechet FJ, Uze G. Interferon-lambda-treated dendritic cells specifically induce proliferation of FOXP3-expressing suppressor T cells. Blood 2006, 107:4417-4423. 10.1182/blood-2005-10-4129, 16478884.
18. Wu Q, Yang Q, Lourenco E, Sun H, Zhang Y. Interferon-lambda1 induces peripheral blood mononuclear cell-derived chemokines secretion in patients with systemic lupus erythematosus: its correlation with disease activity. Arthritis Res Ther 2011, 13:R88. 10.1186/ar3363, 3218903, 21679442.
19. Lin SC, Kuo CC, Tsao JT, Lin LJ. Profiling the expression of interleukin (IL)-28 and IL-28 receptor alpha in systemic lupus erythematosus patients. Eur J Clin Invest 2012, 42:61-69. 10.1111/j.1365-2362.2011.02557.x, 21707611.
20. van Tuyl LH, Vlad SC, Felson DT, Wells G, Boers M. Defining remission in rheumatoid arthritis: results of an initial American College of Rheumatology/European League Against Rheumatism consensus conference. Arthritis Rheum 2009, 61:704-710. 10.1002/art.24392, 2681785, 19405006.
21. Pickens SR, Chamberlain ND, Volin MV, Pope RM, Mandelin AM, Shahrara S. Characterization of CCL19 and CCL21 in rheumatoid arthritis. Arthritis Rheum 2011, 63:914-922. 10.1002/art.30232, 3079365, 21225692.
22. Miyazawa K, Mori A, Okudaira H. Establishment and characterization of a novel human rheumatoid fibroblast-like synoviocyte line, MH7A, immortalized with SV40 T antigen. J Biochem 1998, 124:1153-1162. 10.1093/oxfordjournals.jbchem.a022233, 9832620.
23. Liu MQ, Zhou DJ, Wang X, Zhou W, Ye L, Li JL, Wang YZ, Ho WZ. IFN-lambda3 inhibits HIV infection of macrophages through the JAK-STAT pathway. PLoS One 2012, 7:e35902. 10.1371/journal.pone.0035902, 3338759, 22558263.
24. Li W, Lewis-Antes A, Huang J, Balan M, Kotenko SV. Regulation of apoptosis by type III interferons. Cell Prolif 2008, 41:960-979. 10.1111/j.1365-2184.2008.00558.x, 19040572.
25. Chi B, Dickensheets HL, Spann KM, Alston MA, Luongo C, Dumoutier L, Huang J, Renauld JC, Kotenko SV, Roederer M, Beeler JA, Donnelly RP, Collins PL, Rabin RL. Alpha and lambda interferon together mediate suppression of CD4 T cells induced by respiratory syncytial virus. J Virol 2006, 80:5032-5040. 10.1128/JVI.80.10.5032-5040.2006, 1472058, 16641294.
26. Perlman H, Pope RM. The synovial lining micromass system: toward rheumatoid arthritis in a dish?. Arthritis Rheum 2010, 62:643-646. 10.1002/art.27297, 2878733, 20187157.
27. Reynier F, Petit F, Paye M, Turrel-Davin F, Imbert PE, Hot A, Mougin B, Miossec P. Importance of correlation between gene expression levels: application to the type I interferon signature in rheumatoid arthritis. PLoS One 2011, 6:e24828. 10.1371/journal.pone.0024828, 3197194, 22043277.
28. van Holten J, Smeets TJ, Blankert P, Tak PP. Expression of interferon beta in synovial tissue from patients with rheumatoid arthritis: comparison with patients with osteoarthritis and reactive arthritis. Ann Rheum Dis 2005, 64:1780-1782. 10.1136/ard.2005.040477, 1755294, 15878901.
29. Rosengren S, Corr M, Firestein GS, Boyle DL. The JAK inhibitor CP-690,550 (tofacitinib) inhibits TNF-induced chemokine expression in fibroblast-like synoviocytes: autocrine role of type I interferon. Ann Rheum Dis 2012, 71:440-447. 10.1136/ard.2011.150284, 22121136.
30. Firestein GS, Zvaifler NJ. Peripheral blood and synovial fluid monocyte activation in inflammatory arthritis. II. Low levels of synovial fluid and synovial tissue interferon suggest that gamma-interferon is not the primary macrophage activating factor. Arthritis Rheum 1987, 30:864-871. 10.1002/art.1780300804, 3115274.
31. McInnes IB, Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol 2007, 7:429-442. 10.1038/nri2094, 17525752.